

Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort

Nasir T. Wabe, Michael J. Sorich, Mihir D. Wechalekar, Leslie G. Cleland, Leah McWilliams, Anita T.Y. Lee, Llewellyn D. Spargo, Robert G. Metcalf, Cindy Hall, Susanna M. Proudman, and Michael D. Wiese

ABSTRACT. Objective. To investigate the association between adherence to treat-to-target (T2T) protocol and disease activity, functional outcomes, and radiographic outcomes in early rheumatoid arthritis (RA). **Methods.** Data from a longitudinal cohort of patients with early RA were used. Adherence was determined at each followup visit over 3 years according to predefined criteria. The primary endpoint was remission according to Disease Activity Score in 28 joints (DAS28) and Simplified Disease Activity Index (SDAI) criteria. Functional and radiographic outcomes measured by modified Health Assessment Questionnaire and modified total Sharp score, respectively, were secondary endpoints. **Results.** A total of 198 patients with 3078 clinic visits over 3 years were included in this analysis. After adjusting for relevant variables, although there was no significant association between adherence to T2T and remission rate after 1 year, the associations reached significance after 3 years for both DAS28 (OR 1.71, 95% CI 1.16–2.50; $p = 0.006$) and SDAI criteria (OR 1.94, 95% CI 1.06–3.56; $p = 0.033$). After 3 years, adherence was also associated with improvement in physical function ($\beta = 0.12$, 95% CI 0.06–0.18; $p < 0.0001$). None of the radiographic outcomes were associated with adherence after either 1 or 3 years, although there was a trend for higher adherence to be associated with less radiographic progression at the end of the study ($p = 0.061$). **Conclusion.** Increased adherence to T2T was associated with better longterm disease activity and functional outcomes, which suggests that the benefit of a T2T protocol may be enhanced by ensuring adequate adherence. (J Rheumatol First Release July 15 2016; doi:10.3899/jrheum.151392)

Key Indexing Terms:

TREAT TO TARGET
PHYSICIAN ADHERENCE

CLINICAL GUIDELINES
TREATMENT PROTOCOL

Contemporary rheumatoid arthritis (RA) management involves a tight control strategy called treat to target (T2T), with the aim of maintaining normal physical, psychological, and socioeconomic function through timely control of symptoms and prevention of structural damage^{1,2}. It is a target-driven process whereby treatment is intensified until target is reached². With the advent of the T2T, patients with

RA are now more likely to attain remission and have improved health-related quality of life with less joint damage^{3,4,5,6,7}.

Successful implementation of a T2T in routine clinical practice depends on several factors, starting with early referral and timely commencement of disease-modifying antirheumatic drugs (DMARD), followed by close

From the School of Pharmacy and Medical Sciences, University of South Australia; Sansom Institute for Health Research, University of South Australia; School of Medicine, Flinders University; Department of Rheumatology, Royal Adelaide Hospital; Discipline of Medicine, University of Adelaide, Adelaide, Australia.

N.T. Wabe, MPharm, MSc, PhD candidate, School of Pharmacy and Medical Sciences and Sansom Institute for Health Research; M.J. Sorich, PhD, Associate Professor, School of Pharmacy and Medical Sciences and Sansom Institute for Health Research, and School of Medicine, Flinders University; M.D. Wechalekar, MBBS, MD, FRACP, School of Medicine, Flinders University; L.G. Cleland, PhD, Professor, Department of Rheumatology, Royal Adelaide Hospital; L. McWilliams, BN, Associate Clinical Services Coordinator, Department of Rheumatology, Royal Adelaide Hospital; A.T. Lee, MBBS (Hons), FRACP, PhD, Department of Rheumatology, Royal Adelaide Hospital, and Discipline of Medicine,

University of Adelaide; L.D. Spargo, BSc (Hons), Department of Rheumatology, Royal Adelaide Hospital; R.G. Metcalf, PhD, Department of Rheumatology, Royal Adelaide Hospital; C. Hall, Department of Rheumatology, Royal Adelaide Hospital; S.M. Proudman, MBBS (Hons), FRACP, Associate Professor, Department of Rheumatology, Royal Adelaide Hospital, and Discipline of Medicine, University of Adelaide; M.D. Wiese, PhD, Associate Professor, School of Pharmacy and Medical Sciences and Sansom Institute for Health Research, University of South Australia.

Address correspondence to N.T. Wabe, University of South Australia, School of Pharmacy and Medical Sciences, GPO Box 2471, Adelaide 5001, Australia. E-mail: wabnt001@mymail.unisa.edu.au

Accepted for publication May 27, 2016.

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2016. All rights reserved.

monitoring of disease activity and drug toxicities, all of which require frequent clinic visits^{8,9,10}. A metaanalysis demonstrated that protocolized targeted intensification of treatment is more advantageous than nonprotocolized therapy adjustment¹¹. Adherence to T2T protocol may play an important role in determining the outcome of treatment, but the relationship between the extent of adherence to protocolized escalation of therapy and outcomes of treatment has not yet been established, to our knowledge.

We have described the deviations from a T2T protocol and shown that nonadherence occurred in about one-quarter of followup visits¹². The most common reasons for nonadherence were patient factors, physician's own decisions, drug toxicities, and comorbidities. The objective of this study was to determine the effect of physician adherence to T2T protocol on disease activity, radiographic outcomes, and functional outcomes among recent-onset patients with RA treated with protocolized escalation of DMARD.

MATERIALS AND METHODS

Design and patient population. Patients who were followed for at least 1 year in a longitudinal observational cohort of early RA at the Royal Adelaide Hospital (Adelaide, Australia) were included. Since 2001, consecutive treatment-naïve patients aged 18 years or older with currently active RA according to the 1987 revised American College of Rheumatology (ACR)¹³ or 2010 ACR/European League Against Rheumatism criteria¹⁴ for < 2 years have been enrolled in the cohort.

The following data were obtained at baseline and/or followup visits: sociodemographics, clinical variables, 28-joint Disease Activity Score (DAS28) based on the erythrocyte sedimentation rate, physician's global assessment [PGA; 100 mm visual analog scale (VAS), 100 = worst rating], patient-reported measures [patient global assessment (PtGA), pain and fatigue all measured using 100 mm VAS], physical function [modified Health Assessment Questionnaire (mHAQ) rated on 0 to 3 scale, lower score representing better functioning¹⁵], and helplessness [assessed by Rheumatology Attitudes Index helplessness subscale ranked from 5 to 25, lower score representing lowest degree of helplessness¹⁶] and modified total Sharp score (mTSS).

Ethical approval was obtained from the Royal Adelaide Hospital Research and Ethics Committee, and participants' informed consent was obtained.

Treatment strategy. Patients were managed according to a T2T strategy as described^{4,12,17}. Briefly, participants were initially treated with 3 DMARD [10 mg/week methotrexate (MTX), 500 mg/day sulfasalazine (SSZ) and 400 mg/day hydroxychloroquine (HCQ)]. Further intensification occurred until the target disease activity was achieved according to a structured algorithm (Supplementary Figure 1, available from the authors on request). Injectable corticosteroids were used temporarily if needed to reduce disease activity, while oral corticosteroids were actively discouraged.

Adherence to T2T. At each followup visit, there was an assessment of whether target disease activity was achieved, whether DMARD-related toxicities occurred, and whether therapy modification was needed¹². Assessment of adherence was made against local clinic guidelines, which state that a decision regarding treatment intensification is to occur every 3-6 weeks initially and then every 3 months unless treatment target was achieved or significant toxicity occurred (Table 1). First, the adherence rate was expressed as the proportion of visits with correct adherence to the protocol (i.e., dividing the no. visits that were adherent by the total no. visits over the specified time period). To explore whether better outcomes were due to better adherence, or whether those with more responsive disease had better outcomes because they had less opportunity to be nonadherent, a modified

version of adherence was also calculated whereby the denominator included only clinic visits during which drug (or drug dose) change was indicated.

Outcome measures. The primary endpoint was the rate of remission according to DAS28 and the Simplified Disease Activity Index (SDAI) criteria at Year 1 and Year 3. Accordingly, remission was defined as DAS28 < 2.6 and SDAI ≤ 3.3^{18,19,20}. Secondary outcomes were physical function¹⁵ and radiographic outcomes [absolute change and progression (i.e., increase of ≥ 1)] of mTSS²¹ at Year 1 and Year 3.

Statistical analysis. For the purposes of analysis, the adherence level was converted into a decile (i.e., as a 10% increment) to aid with interpretation. Adherence levels at Year 1 and Year 3 were used in analysis of outcomes after 1 and 3 years, respectively. Logistic regression was used to determine the effect of adherence after adjustment for conventional predictors of outcome. Any variable having a p value of < 0.25 in univariate analysis at 1 or 3 years was selected as a candidate for the multivariate analysis²². The association was reported using OR with 95% CI. In the case of continuous outcomes, univariate and then multivariate linear regression was performed as above, and a β coefficient with a 95% CI was used as the measure of association. Analysis was performed using Statistical Package for Social Sciences (SPSS) for Windows version 21.0 (SPSS Inc.).

RESULTS

Baseline patient characteristics. Out of 231 patients, 33 were excluded because they were lost to followup (n = 21), had short followup (10), or had other medical conditions (n = 2; Supplementary Figure 2, available from the authors on request). With 1931 clinic visits, 198 patients completed 1 year of treatment. With a total of 3078 clinic visits, 149 patients completed 3 years of treatment. The majority of patients were female (71.7%), rheumatoid-factor positive (62.6%), and shared epitope-positive (61.0%), and the mean (SD) DAS28 was 5.5 (± 1.3; Table 2).

DMARD usage patterns and adherence to T2T. About 90% (n = 175) of patients were initiated on triple DMARD therapy. Over the 3-year followup, 82.6% of individuals required a dose escalation and/or addition of new DMARD. Treatment intensification was rapid with a median time to first intensification of 6 weeks and on average each patient received 3.6 DMARD during the treatment period.

Table 3 presents treatment characteristics during the followup period. The median dose of MTX was 20 mg/week at Year 1 and 15 mg/week at Year 3, while that of SSZ and HCQ was 2 g/day and 400 mg/day, respectively, at both years 1 and 3. Leflunomide (LEF) was added in slightly over half of the patients, and < 10% of the cohort received a biological DMARD by Year 3. Injectable corticosteroids were received by around two-thirds of patients (Table 3).

From the total of 3078 clinic visits over 3 years, the mean proportion of visits that were adherent to T2T protocol was 81.5% after 1 year and 77.5% after 3 years.

Correlates of disease activity outcome. Remission rate according to DAS28 and SDAI was attained by 28.3% and 18.3% at 6 months, respectively. After 1 year, 42.3% and 24.2% patients achieved DAS28 and SDAI remission, respectively, and these increased to 46.4% (DAS28) and 31.5% (SDAI) by the end of Year 3.

Baseline variables associated with either DAS28 or SDAI

Table 1. Assessment of adherence to a T2T protocol.

Target Achieved	Significant Toxicity Occurred ¹	Adherent	Nonadherent
No	No	Intensified	Continued/tapered/discontinued
No	Yes	Intensified ²	Continued/tapered/discontinued ³
Yes	No	Continued	Intensified/tapered/discontinued
Yes	Yes	Continued/tapered/discontinued	Intensified
Yes/No	Yes/No		Discontinuation of all DMARD ⁴

¹Severe toxicities, according to physician's assessment, deemed to be unfavorable to the health of the patient. ²By definition it could be considered adherent, but when significant toxicity occurred, physicians rarely intensified therapy at the same visit. ³If significant toxicity occurred, therapy escalation is not expected. However, it is still considered nonadherent because the target has not been achieved. ⁴Stopping all DMARD regardless of patient's disease activity or toxicity status was considered nonadherent. T2T: treat to target; DMARD: disease-modifying antirheumatic drug.

Table 2. Baseline patient characteristics (n = 198). Data are n (%) or median (interquartile range).

Characteristics	Values
Female	142 (71.7)
Age, yrs	56.2 (44.6–66.5)
Body mass index, kg/m ²	27.2 (24.0–30.8)
Current and former smoker	107 (54.0)
Weeks of polyarthritis at baseline	16 (12–27)
RF positive	124 (62.6)
Anti-CCP positive	109 (56.2)
Shared epitope positive	119 (61.0)
DAS28	5.5 (4.7–6.4)
PGA, VAS, 0–100 mm	54.0 (34.0–70.0)
Erosive disease	36 (23.5)
Modified total Sharp score	2.0 (0.0–7.0)
Physical function, mHAQ, 0–3	0.63 (0.25–1.13)
Pain, VAS, 0–100 mm	57.0 (30.5–75.0)
Fatigue, VAS, 0–100 mm	50.5 (23.0–69.0)
PtGA, VAS, 0–100 mm	49.0 (26.0–64.8)
Helplessness, RAI, 5–25	14.0 (10.0–18.3)

VAS: visual analog scale; mHAQ: modified Health Assessment Questionnaire; RAI: Rheumatology Attitudes Index; RF: rheumatoid factor; anti-CCP: anticyclic citrullinated peptide antibodies; DAS28: Disease Activity Score in 28 joints; PGA: physician's global assessment; PtGA: patient's global assessment.

Table 3. Treatment characteristics during the followup visits.

Characteristics	Year 1, n = 198	Year 3, n = 149
MTX dose, mg/week, median (IQR)	20.0 (10.0–25.0)	15.0 (8.75–25.0)
MTX dose ≥ 20 mg/week, n (%)	108 (54.5)	61 (40.9)
SSZ dose, g/day, median (IQR)	2.0 (0.0–3.0)	2.0 (0.0–3.0)
SSZ dose ≥ 2 g/day, n (%)	114 (57.8)	79 (53.0)
HCQ dose, mg/day, median (IQR)	400.0 (0)	400.0 (0)
Concomitant DMARD, n (%)		
Leflunomide	65 (32.8)	75 (50.3)
Gold injection	8 (4.0)	23 (15.4)
Biologics	3 (1.5)	14 (9.4)
Cyclosporine	1 (0.5)	4 (2.7)
Azathioprine	1 (0.5)	2 (1.3)
Injectable corticosteroids, n (%)	120 (60.6)	108 (72.3)

MTX: methotrexate; SSZ: sulfasalazine; HCQ: hydroxychloroquine; DMARD: disease-modifying antirheumatic drug.

remission after 1 year were body mass index (BMI), DAS28, PGA, mHAQ, pain, helplessness, and fatigue. After 3 years, baseline smoking status, pain, and fatigue were associated with both DAS28 and SDAI remission. Concomitant use of new DMARD, more frequent clinic visits, or occurrence of a significant toxicity were inversely associated with remission after both 1 and 3 years, whereas individuals with longer time to first DMARD dose escalation were more likely to achieve remission after 1 but not 3 years (Table 4).

After correcting for these variables, there was no significant association between adherence and remission rate after 1 year (DAS28: OR 1.61, *p* = 0.124; SDAI: OR 1.34, *p* = 0.390), but the associations reached significance after 3 years for both DAS28 (OR 1.71, *p* = 0.006) and SDAI criteria (OR 1.94, *p* = 0.033). Nonsmokers were more likely to achieve remission as measured by both DAS28 (OR 7.14, *p* = 0.014) and SDAI (OR 14.51, *p* = 0.027) after 3 years. On the other hand, the rate of remission was lower among patients who required additional DMARD after 1 year, although there was no association after 3 years (Table 5).

Sensitivity analysis. In the following analyses, results are presented after adjustment for baseline DAS28, BMI, smoking status, PGA, mHAQ, helplessness, pain, fatigue, weeks to dose escalation, frequency of clinic visits, existence of significant toxicity, and the need for new DMARD.

Categorizing adherence using 80% cutoff. There were no major differences between adherence > 80% and ≤ 80% with regard to doses of MTX, SSZ, and HCQ at 1 and 3 years. However, usage of concomitant DMARD and injectable corticosteroids were more common among patients with adherence < 80% (Supplementary Table 1, available from the authors on request).

At Year 1, there were no significant differences in remission rate between adherence groups in multivariate analysis. However, patients with adherence ≥ 80% were more likely to achieve remission according to both DAS28 (OR 5.08, *p* = 0.004) and SDAI (OR 10.37, *p* = 0.006) criteria compared to participants with adherence < 80% after 3 years (Table 6).

Modified definition of adherence. Of the visits that required dose/drug modifications, therapy adjustments were indicated

Table 4. Univariate analysis of the factors associated with remission after 1 and 3 years. Data are OR (95% CI).

Variables	Year 1, n = 198		Year 3, n = 149	
	DAS28	SDAI	DAS28	SDAI
Adherence level (10% increment)	2.01 (1.45–2.69)	2.00 (1.40–2.88)	2.11 (1.58–2.80)	2.14 (1.48–3.09)
Weeks to dose escalation	1.01 (1.00–1.02)	1.01 (1.00–1.01)	1.01 (0.99–1.02)	1.01 (1.00–1.02)
Addition of new DMARD (yes vs no)	0.17 (0.08–0.32)	0.16 (0.07–0.35)	0.16 (0.08–0.33)	0.17 (0.07–0.40)
Frequency of clinic visits	0.76 (0.64–0.91)	0.79 (0.65–0.96)	0.81 (0.74–0.89)	0.81 (0.74–0.89)
Significant toxicity (yes vs no)	0.49 (0.26–0.94)	0.42 (0.19–0.95)	0.20 (0.10–0.41)	0.27 (0.12–0.62)
Baseline BMI, kg/m ²	0.94 (0.89–0.99)	0.99 (0.94–0.06)	0.96 (0.90–1.02)	0.97 (0.90–1.04)
Baseline nonsmoker vs current smoker	1.78 (0.76–4.16)	1.27 (0.48–3.35)	3.52 (1.22–10.16)	5.31 (1.17–24.04)
Baseline DAS28	0.73 (0.57–0.93)	0.96 (0.93–0.98)	0.88 (0.67–1.15)	0.98 (0.95–1.01)
Baseline PGA	0.98 (0.97–0.99)	0.98 (0.97–0.99)	0.97 (0.98–1.01)	0.99 (0.97–1.01)
Baseline physical function	0.56 (0.32–0.99)	0.34 (0.17–0.75)	0.71 (0.38–1.32)	0.47 (0.22–1.01)
Baseline pain	0.98 (0.97–0.99)	0.98 (0.97–0.99)	0.98 (0.97–0.96)	0.97 (0.96–0.99)
Baseline helplessness	0.92 (0.86–0.98)	0.93 (0.86–0.99)	0.95 (0.88–1.01)	0.89 (0.82–0.96)
Baseline fatigue	0.98 (0.97–0.99)	0.98 (0.97–0.99)	0.98 (0.97–0.99)	0.98 (0.97–0.99)

These factors did not show significant association with outcome: sex, age, disease duration, RF status, anti-CCP status, SE status, erosion score, and mTSS. For dichotomous outcomes, the reference category is indicated with italics. All variables included here were significantly associated with remission at 1 and/or 3 years. DAS28: Disease Activity Score in 28 joints; SDAI: Simplified Disease Activity Index; BMI: body mass index; PGA: physician's global assessment; RF: rheumatoid factor; anti-CCP: anticyclic citrullinated peptide antibodies; SE: shared epitope; mTSS: modified total Sharp score; DMARD: disease-modifying antirheumatic drug.

Table 5. Multivariate predictors of remission after 1 and 3 years. Data are OR (95% CI) except for Nagelkerke R².

Variables	Year 1, n = 198		Year 3, n = 149	
	DAS28	SDAI	DAS28	SDAI
Adherence level (10% increment)	1.61 (0.88–2.96)	1.34 (0.68–2.62)	1.71 (1.16–2.50)*	1.94 (1.06–3.56)*
Addition of new drug (yes vs no)	0.14 (0.04–0.49)*	0.08 (0.01–0.4)*	0.77 (0.21–2.79)	0.84 (0.17–4.03)
Frequency of clinic visits	0.80 (0.56–1.14)	0.89 (0.62–1.27)	0.90 (0.77–1.05)	0.81 (0.65–0.99)*
Baseline nonsmoker vs current smoker	3.28 (0.76–14.19)	1.58 (0.36–6.95)	7.14 (1.50–33.0)*	14.51 (1.34–156.3)*
Nagelkerke R ²	0.516	0.398	0.484	0.510

*p < 0.05. Variables with a p value of < 0.25 in univariate analysis were included in this multivariate analysis. A backward elimination technique was used to identify independent predictors of remission. For dichotomous outcomes, the reference category was indicated using italics. DAS28: Disease Activity Score in 28 joints; SDAI: Simplified Disease Activity Index.

Table 6. Univariate and multivariate predictors of remission after 1 and 3 years. Data are OR (95% CI) except for Nagelkerke R².

Variables	Year 1, n = 198		Year 3, n = 149	
	DAS28	SDAI	DAS28	SDAI
Univariate				
Adherence level (≥ 80% vs < 80%)	3.70 (1.96–6.97)*	4.85 (2.10–11.23)*	6.87 (3.21–14.66)*	7.31 (2.78–19.19)*
Modified adherence (10% increment)	1.26 (1.03–1.54)*	1.22 (0.97–1.54)	1.57 (1.26–1.95)*	1.75 (1.35–2.27)*
Multivariate				
Adherence level (≥ 80% vs < 80%)	1.81 (0.57–5.70)	3.06 (0.76–12.41)	5.08 (1.67–15.45)*	10.37 (1.94–55.49)*
Modified adherence (10% increment)	1.14 (0.83–1.56)	1.00 (0.67–1.36)	1.45 (1.06–1.98)*	1.49 (0.99–2.25)
Nagelkerke R ²	0.446	0.384	0.447	0.514

* p < 0.05. Multivariate analysis was controlled for baseline DAS28, BMI, smoking status, PGA, physical function, helplessness, pain, fatigue, weeks to dose escalation, frequency of clinic visits, addition of further DMARD, and existence of significant toxicity (yes/no). DAS28: Disease Activity Score in 28 joints; SDAI: Simplified Disease Activity Index; BMI: body mass index; PGA: physician's global assessment; DMARD: disease-modifying antirheumatic drug.

in 1594 of 3078 (51.8%) total clinic visits over 3 years. Adherence with the treatment protocol was observed in 956 (60%) of these visits with mean proportion of 68.0% per patient at the end of the followup period; lower than the

adherence rate observed when total number of visits was included.

After correcting for other predictors, there was no association between the modified level of adherence and remission

after 1 year of followup, but after 3 years there was a significant association with DAS28 remission (OR 1.45, $p = 0.019$) and a trend for an association with SDAI remission (OR 1.49, $p = 0.056$; Table 6).

Effect on physical function and radiographic outcome. The mean (SD) reduction in mHAQ from baseline to Year 1 and Year 3 was 0.42 (0.58) and 0.46 (0.58), respectively. At Year 1, there was no association between adherence and change from baseline in mHAQ score (univariate analysis), but there was a significant association after 3 years. After controlling for baseline DAS28, PGA, pain, PtGA, fatigue, and helplessness, adherence level was significantly associated with improvement in mHAQ [$\beta = 0.12$ (95% CI 0.06–0.18); $p < 0.0001$], i.e., a 10% increment in adherence level was associated with a 0.12-unit improvement in mHAQ score.

The median (IQR) mTSS at baseline was 2.0 (0.0–7.0). The median (IQR) increase in mTSS from baseline to years 1 and 3 was 0.0 (0.0–2.0) and 2.0 (0.0–5.0), respectively, and radiographic progression occurred in 43.2% of patients at Year 1 and 63.3% of patients at Year 3. Generally, none of the radiographic outcomes were statistically significantly associated with adherence level, but there was a trend for higher adherence to be associated with a lower increase in mTSS at Year 3 [$\beta = -0.74$ (95% CI -0.04 to 1.51); $p = 0.061$].

DISCUSSION

In our cohort, a strong association between adherence to T2T and longterm treatment outcomes was observed. Specifically, higher adherence was associated with higher remission rates and greater improvement in physical function, and this relationship was maintained even after correcting for the indicators of hard-to-treat disease such as the more frequent clinic visits, the need for additional DMARD, and higher baseline disease activity. Given that easier-to-control RA is likely associated with both better outcomes and higher adherence, we confirmed that when adherence was calculated based only on the clinic visits during which a change in treatment was indicated, an association between adherence and remission was still apparent.

The results from the current study highlight that implementing a T2T protocol is not enough to guarantee better treatment outcomes; appropriate adherence to the treatment protocol substantially increases the likelihood of attaining better outcomes. Although we found superior longterm disease activity outcomes for patients with better adherence, full adherence to the T2T protocol is not always possible because toxicity, comorbidities, patient/physician reasons, and other related factors have previously been shown to contribute to nonadherence^{9,10,12,23}. The effects of modifiable factors causing nonadherence such as patient resistance and some physicians' reasons should be minimized where possible.

This study has some important clinical implications. First,

to the extent that adherence is a negotiation between physician and patient, in which the physician's beliefs and actions play a leading role, the findings should fortify the physician's conviction to follow the rules and to transfer her/his belief in the rules to the patient, a practice that is likely to improve adherence. Second, baseline disease activity appears important in achieving early outcomes, but adherence increases in importance as time with a treatment progresses, suggesting, similar to the "window of opportunity" hypothesis²⁴, that good short-term adherence promotes lower longterm disease activity. Finally, because drug toxicity is a reason for nonadherence with the dose escalation rules¹², and nonadherence is associated with poorer outcomes, patients could be encouraged to test their tolerance by explaining that the toxicities are rarely dangerous with appropriate surveillance, and if treatment is tolerated, a favorable outcome is likely.

In our present study, about half of the patients reached DAS28 remission and one-third of them achieved SDAI remission after 3 years of intensive treatment. This was comparable to other cohorts^{25,26}, although lower than that achieved when anti-tumor necrosis factor agents are used as initial therapy⁷. There are 2 points that are worth mentioning here. First, members of our cohort were early adopters of T2T, such that all individuals in the cohort were treated according to this approach, whereas in many other practices the rate of T2T increased markedly over the past 10–15 years, which may explain why some large cohorts have demonstrated substantially improved outcomes during this period²⁵. Second, biological agents are not available under the Australian subsidy schemes until a patient has relatively high active disease despite 6 months of synthetic agents. Such a system creates problems for individuals who have low to moderate disease activity, because they do not qualify for biological agents, but have not achieved optimal outcomes according to contemporary standards. The clinicians' dilemma is a potential incentive to artificially increase disease activity, although this is not our practice²⁷. Therefore, remission rates may be lower than expected if biological agents are used more liberally.

Similar to our findings, smoking status has previously been shown to be negatively associated with remission²⁸, and the finding that addition of DMARD was associated with a lower remission rate was not surprising, because addition of new drugs indicates individuals who have disease that is more difficult to treat. After adding a new drug, adherence to T2T protocol declined and remission was less common, further indicating the influence of adherence on treatment outcome. It may also be that both patients and physicians are more willing to tolerate higher disease activity if they have never experienced a good outcome — for example, once LEF is added, addition of the next DMARD may be perceived as more toxic, and hence more active disease may be acceptable.

The effect of adherence to the T2T on radiographic

outcomes was less remarkable than on disease activity and functional outcomes. The reason for lack of difference in radiographic outcome may be the low overall rate of radiographic progression in the entire population, relatively short followup, or simply the overall effectiveness of the T2T with conventional DMARD, and may have less to do with adherence level. In this regard, it is notable that intensive use of conventional DMARD appears to provide little additional benefit in preventing radiographic progression compared to standard therapy^{3,29}.

To the best of our knowledge, this is the first study to explore the relationship between adherence to T2T and the outcomes of therapy. Earlier studies have been limited mostly to identifying reasons for nonadherence^{10,30}, exploring barriers to achieving the desired treatment goal⁹, exploring reasons for resistance to therapy modification³¹, examining how patients and physicians approach the decision to escalate treatment, or identifying factors that affect the decision to intensify therapy^{32,33}. Our present study is advantageous in that it highlights the importance of adhering to treatment guidelines to achieve optimal clinical outcomes when following a T2T protocol.

It is worth mentioning that some of our patients received high or low doses of omega-3 fatty acids, and others in the cohort were encouraged to take high-dose omega-3 fatty acids, but this was not mandated. Analysis of these patients (those randomized to high-dose vs low-dose omega-3 fatty acids) did not show any significant difference in adherence to T2T between them and the rest of the patients. Further, patients seen in our clinic have already been triaged as having RA and they almost all agree to enroll in the cohort. The number of participants included in the study is a relatively accurate reflection of the number of individuals who presented to the clinic in our rheumatology department between 2001 and 2014. This makes recruitment bias unlikely to be apparent in the study.

There are some limitations to consider when interpreting the findings of our current study. We conducted our study at a single hospital and used only 1 form of T2T approach. Thus, the findings may not be representative of all other treatment approaches within a T2T framework. Studies should be conducted to determine whether simpler treatment regimens improve adherence to T2T. Given the observational nature of our study, it is difficult to tease apart the effects of better adherence, good treatment outcomes, and disease that is inherently easier to control, and therefore conclusions regarding the causal relationships should be viewed with a degree of caution. However, because better treatment outcome was associated with increased adherence even after adjusting for several confounding variables and considering just the visits during which a change in treatment was indicated, the results of our present study are highly suggestive that physician adherence to protocol may be one of the main factors determining the outcome of treatment in

RA following T2T. The first participants in this study began treatment in 2001 when the benefits of T2T had not yet been fully realized or biological DMARD were not commonly available. Although there has since been increased awareness of T2T, and further evidence of its effectiveness and increased uptake in clinical practice, subgroup analysis did not show any differences in treatment outcome and adherence to T2T, according to the date treatment was initiated (data not shown). This could be due to stable personnel and consistent rheumatologist practice patterns over the years in our study. We assumed that adherence to T2T was equally distributed among treating physicians because patients were not assigned to a single rheumatologist throughout followup. However, it cannot be discounted that differences in the pattern of adherence to T2T protocol among physicians may affect patients' behavior and the outcome of treatment.

Higher adherence to a T2T strategy was associated with better longterm disease activity and functional outcomes, and it is therefore possible to increase the benefits of T2T in day-to-day clinical practice by maximizing adherence to the protocol.

ACKNOWLEDGMENT

The authors are grateful to all the rheumatologists and rheumatology nurses involved in the treatment and care of the study patients as well as to those patients who participated in this study.

REFERENCES

1. Moreland LW, Russell AS, Paulus HE. Management of rheumatoid arthritis: the historical context. *J Rheumatol* 2001;28:1431-52.
2. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. *Ann Rheum Dis* 2010;69:631-7.
3. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. *Lancet* 2004;364:263-9.
4. Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, et al. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. *Semin Arthritis Rheum* 2007;37:99-111.
5. Schipper LG, Vermeer M, Kuper HH, Hoekstra MO, Haagsma CJ, Den Broeder AA, et al. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. *Ann Rheum Dis* 2012;71:845-50.
6. Vermeer M, Kuper HH, Hoekstra M, Haagsma CJ, Posthumus MD, Brus HL, et al. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. *Arthritis Rheum* 2011;63:2865-72.
7. Vermeer M, Kuper HH, Moens HJ, Drossaers-Bakker KW, van der Bijl AE, van Riel PL, et al. Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: three year results of the DREAM remission induction cohort. *Arthritis Care Res* 2013;65:1219-26.

8. Palmer D, El Miedany Y. Rheumatoid arthritis: recommendations for treat to target. *Br J Nurs* 2014;23:310-5.
9. Tymms K, Zochling J, Scott J, Bird P, Burnet S, de Jager J, et al. Barriers to optimal disease control for rheumatoid arthritis patients with moderate and high disease activity. *Arthritis Care Res* 2014;66:190-6.
10. Vermeer M, Kuper HH, Bernelot Moens HJ, Hoekstra M, Posthumus MD, van Riel PL, et al. Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort. *Arthritis Res Ther* 2012;14:R254.
11. Schipper LG, van Hulst LT, Grol R, van Riel PL, Hulscher ME, Fransen J. Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. *Rheumatology* 2010;49:2154-64.
12. Wabe N, Sorich M, Wechalekar M, Cleland L, McWilliams L, Lee A, et al. Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years. *Arthritis Res Ther* 2015;17:48.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31:315-24.
14. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum* 2010; 62:2569-81.
15. Pincus T, Summey JA, Soraci SA Jr., Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. *Arthritis Rheum* 1983;26:1346-53.
16. DeVellis RF, Callahan LF. A brief measure of helplessness in rheumatic disease: the helplessness subscale of the Rheumatology Attitudes Index. *J Rheumatol* 1993;20:866-9.
17. Wabe N, Sorich MJ, Wechalekar MD, Cleland LG, McWilliams L, Lee A, et al. Determining the acceptable level of physician compliance with a treat-to-target strategy in early rheumatoid arthritis. *Int J Rheum Dis* 2015 Dec 22 (E-pub ahead of print).
18. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. *Ann Rheum Dis* 2009;68:954-60.
19. Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. *Arthritis Rheum* 1981;24:1308-15.
20. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. *Rheumatology* 2003;42:244-57.
21. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. *J Rheumatol* 2000;27:261-3.
22. Bursac Z, Gauss CH, Williams DK, Hosmer D. Purposeful selection of variables in logistic regression. *Source Code Biol Med* 2008;3:17.
23. Wabe N, Sorich M, Wechalekar M, Cleland L, McWilliams L, Lee A, et al. Drug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: does ceasing therapy due to toxicity worsen outcomes in long term? *Int J Clin Pract* 2016;70:340-50.
24. Landewe RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markkuse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. *Arthritis Rheum* 2002;46:347-56.
25. Aga AB, Lie E, Uhlig T, Olsen IC, Wierød A, Kalstad S, et al. Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000–2010. *Ann Rheum Dis* 2015;74:381-8.
26. Benbouazza K, Rkain H, Benchekroun B, Amine B, Bzami F, Benbrahim L, et al. Remission in early rheumatoid arthritis treated with conventional DMARDs. Results of a two-year follow-up study of El Ayachi Moroccan cohort. *Joint Bone Spine* 2012;79:43-6.
27. Hopkins AM, Proudman SM, Vitry AI, Sorich MJ, Cleland LG, Wiese MD. Ten years of publicly funded biological disease-modifying antirheumatic drugs in Australia. *Med J Aust* 2016;204:64-8.
28. Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. *Rheumatology* 2006;45:1558-65.
29. Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). *Ann Rheum Dis* 2007;66:1443-9.
30. Markkuse IM, Dirven L, Han KH, Runday HK, de Sonnaville PB, Kerstens PJ, et al. Evaluating adherence to a treat-to-target protocol in recent-onset rheumatoid arthritis: Reasons for compliance and hesitation. *Arthritis Care Res* 2016;68:446-53.
31. Wolfe F, Michaud K. Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices. *Arthritis Rheum* 2007;56:2135-42.
32. Kievit W, van Hulst L, van Riel P, Fraenkel L. Factors that influence rheumatologists' decisions to escalate care in rheumatoid arthritis: results from a choice-based conjoint analysis. *Arthritis Care Res* 2010;62:842-7.
33. van Hulst LT, Kievit W, van Bommel R, van Riel PL, Fraenkel L. Rheumatoid arthritis patients and rheumatologists approach the decision to escalate care differently: results of a maximum difference scaling experiment. *Arthritis Care Res* 2011;63:1407-14.